China Pediatric Pharm. Inc. (fka CPDU)

[db7]

China Pediatric Pharmaceuticals, Inc. Files Application for NASDAQ Listing




China Pediatric Pharmaceuticals, Inc. (OTC Bulletin Board: CPDU) ("China Pediatric Pharmaceuticals " or the "Company"), today announced it has applied for listing approval on the NASDAQ Capital Market (“NASDAQ”)

“This is an important milestone for China Pediatric Pharmaceuticals, and we are committed to working with NASDAQ to fulfill all of its listing requirements,” said Mr. Jun Xia, Chairman and Chief Executive Officer. “As a senior exchange NASDAQ is well suited for high-growth companies such as China Pediatric Pharmaceuticals that meet its stringent listing requirements. With a NASDAQ listing, our visibility will increase among investors who follow companies like ours, improving trading volume and liquidity. This should, in turn, attract new investors to our Company.” The application is subject to review by NASDAQ's Listing Qualifications Department for compliance with all NASDAQ Capital Market requirements. The Company's common stock will continue to trade on the OTC Bulletin Board under its current symbol, CPDU, until the Company is notified of its acceptance. CPDU believes it satisfies all of the listing qualifications associated with this application. We hope to receive approval to list on NASDAQ within two to three months

About China Pediatric Pharmaceuticals, Inc. China Pediatric Pharmaceuticals, Inc. has its headquarters in Xi’an, Shaanxi Province, China. The Company identifies, discovers, develops manufactures and distributes both prescription and over-the counter, including both conventional and Traditional Chinese Medicines (“TCMs”), pharmaceutical products for the treatment of some of the most common ailments and diseases, with pediatric medicine as its focus. China Pediatric Pharmaceuticals, Inc.’s manufacturing facility located in Baoji City, Shaanxi Province. The Company distributes its high value, branded medicines, both prescription and OTC, through exclusive territory agents who sell our products directly to local pharmacies who in turn sell them to their retail customers. For the nine months ended September 30, 2009, Revenue was $ 11,323,143 and Net Income was $ 2,583,391 or $0.31 per share. As at September 30, 2009, Shareholders’ Equity was $ 11,613,667 and Total Assets were $ 15,164,459. For more information go to: www.jialipharma.com For more information, please contact: China Pediatric Pharmaceuticals, Inc

Mr. Jun Xia, Chief Executive Officer Mr. Minggang Xiao, Chief Financial Officer Ms. Vivian Juan Wei, Vice President, Corporate Affairs 9th Floor, No. 29 Nanxin Street, Xi’an, Shaanxi Province, P.R.C., 710004 Phone: [phone] Email: [e-mail] Website: www.jialipharma.com Safe Harbor Statement This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements, including but not limited to, the company's ability to raise additional capital to finance the company's activities; the effectiveness, profitability, and the marketability of its products; legal and regulatory risks associated with the share exchange; the future trading of the common stock of the company; the ability of the company to operate as a public company; the period of time for which its current liquidity will enable the company to fund its operations; the company's ability to protect its proprietary information; general economic and business conditions; the volatility of the company's operating results and financial condition; the company's ability to attract or retain qualified senior management personnel and research and development staff; and other risks detailed in the company's filings with the Securities and Exchange Commission and available on its website at http://www.sec.gov. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the companies and the industry. The company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law. Although the company believes that the expectations expressed in these forward looking statements are reasonable, they cannot assure you that their expectations will turn out to be correct, and investors are cautioned that actual results may differ materially from the anticipated results